Abstract: Stable aqueous leucoindigo solution comprising an aromatic amine in the form of aniline or aniline and N-methylaniline, wherein said leucoindigo is in the form of an alkali metal salt; wherein the concentration of the aromatic amine is below 40 ppm determined according to ISO 14362-1:2017(E); and wherein the concentration of the leucoindigo salt is in a concentration range of from 10 to 45% by weight based on the total weight of the solution, and wherein the stability of the solution is measured at a temperature of 23° C.; or wherein the concentration of the leucoindigo salt is in a concentration range of from 45 to 65% by weight based on the total weight of the solution, and wherein the stability of the solution is measured at a temperature of 60° C.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: Smac mimetics that inhibit IAPs.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Abstract: The invention is directed to compounds and methods for treating protein folder disorders. In certain embodiments the invention provides compounds and methods for treating neurodegenerative diseases such as Alzheimer's disease, tauopathy, cerebral amyloid angiopathy, Lewy body disease, dementia, Huntington's disease and prion-based spongiform encelopathy. The invention further provides compounds, methods and pharmaceutical compositions for inhibiting tau protein, A? protein or ?-synuclein protein aggregation.

Abstract: 4-bromomethyl-2?-formylbiphenyl and 4-bromomethyl-2?-hydroxymethylbiphenyl are useful starting material for the preparation various angiotenzin II antagonists, which are prepared from 4-bromomethyl-2?-cyanobiphenyl or 4?-bromomethylbiphenylcarboxyilic derivatives using selected hydride reagent.

Abstract: The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to such inhibition.

Abstract: The present invention relates to a time temperature indicator for indicating temperature change over time, comprising an immobilized enzyme and a substrate of the enzyme, wherein the reaction of the substrate catalyzed by the enzyme produces a reaction product in a time and temperature dependent manner and wherein the formation of the reaction product can be detected by monitoring a physical characteristic of the substrate and/or the product which is linked to its concentration. The invention further relates to a method of time temperature indication comprising the step of an enzyme-catalyzed reaction, a method of printing the enzyme-based time temperature indicator on a packaging material or a label, a printing ink or printing ink concentrate comprising components of the enzyme-based time temperature indicator and a packaging material or a label comprising the enzyme-based time temperature indicator.

Abstract: The invention relates to indole acetic acid compounds which function as antagonists of the CRTH2 receptor. The invention also relates to the use of these compounds to inhibit the binding of prostaglandin D2 and its metabolites or certain thromboxane metabolites to the CRTH2 receptor and to treat disorders responsive to such inhibition.

Abstract: New alkali and earth-alkali salts of telmisartan in amorphous form and a new crystalline sodium salt of telmisartan have been prepared by preparing a solution despite low solubility of telmisartan and rapidly vacuum evaporating to dryness.

Abstract: The present invention relates to methods for the screening of gamma secretase modulators, preferably inhibitors as well as to the use of Eph receptor inhibitors for the treatment of neurodegenerative diseases.

Abstract: This invention provides for labeling reagents, labeled targets and processes for preparing labeling reagents. The labeling reagents can take the form of cyanine dyes, xanthene dyes, porphyrin dyes, coumarin dyes or composite dyes. These labeling reagents are useful for labeling probes or targets, including nucleic acids and proteins. These reagents can be usefully applied to protein and nucleic acid probe based assays. They are also applicable to real-time detection processes.

Abstract: Concentrated leuco indigo solutions useful for dyeing cellulosic textile material consist essentially of from 25 to 55% by weight of leuco indigo in the form of the leuco indigo salt, an amount which is essentially stoichiometrically sufficient to convert the leuco indigo into the neutral leuco indigo salt of a mixture of at least two alkali metal hydroxides wherein none of the alkali metal hydroxides accounts for more than 70 mol %, and water.

Abstract: The invention relates to novel soluble pigment precursors possessing not only higher thermal stability but also improved solubility characteristics and to a process for mass coloration of high temperature polymers that utilizes these novel soluble pigment precursors. The pigment precursors of the invention are essentially of the formula A(B)x  (I) where x is an integer from 1 to 8, A is the radical of a chromophore of the quinacridone, anthraquinone, perylene, indigo, quinophthalone, indanthrone, isoindolinone, isoindoline, dioxazine, azo, phthalocyanine or diketopyrrolopyrrole series, this radical being linked with xB groups via one or more heteroatoms, these heteroatoms being selected from the group consisting of N, O and S and forming part of the radical A, and B is hydrogen or a group of the formula although at least one B group is not hydrogen and when x is from 2 to 8 the B groups may be identical or different.

Abstract: Molecular mimetics of unique epitopes of Neisseria meningitidis serogroup B ("MenB") are disclosed. Compositions containing such molecular mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody responses.

Abstract: Granular leuco vat-dye preparations containing, as essential components, leuco vat-dye, reducing agents and alkaline metal hydroxide, and the production of said preparations and their use in dyeing cellulose-containing textile materials.

Abstract: Compounds are provided having the capability of binding therapeutically active substances to lipid containing bio-compatible particles, such as cells or viruses. These compounds include a bio-affecting moiety, comprising a therapeutically active substance, which is linked via a linking moiety to at least one hydrocarbon substituent selected so that the compounds is sufficiently non-polar to impart lipid binding capability to the compound. Thus, compounds of the invention are useful for site-selective delivery of therapeutic agents, and retention thereof at the selected site.Methods are provided for using various compounds of the invention in treatment of diseases or other pathological conditions. For example, methods are provided for treatment of: (1) post-angioplasty restenosis; (2) rheumatoid arthritis; (3) tumor cell proliferation, particularly tumor cells associated with ovarian cancer; and (4) psoriasis.

Abstract: Novel squarylium dyestuffs are formed by condensing one molecular equivalent of squaric acid with two molecular equivalents of a heterocyclic intermediate of the formula ##STR1## in which X is an optionally substituted ethylene or o-phenylene group; Y is an optionally substituted methylene or imino group, oxygen, sulfur, selenium or (if X is ethylene) a direct bond; and R.sub.1 through R.sub.5 are various substituents or (except for R.sub.2 and R.sub.5) hydrogen. A preferred class of dyestuffs are those formed from intermediates in which Y is methylene or a direct bond, the former including 7-acylaminotetrahydroquinolines and the latter including 6-acylaminoindolines. Thus, two molecular equivalents of each of 1-methyl-7-acetamido-1,2,3,4-tetrahydroquinoline and 6-acetamido-1,2,3, 3-tetramethylindoline were condensed with one molecular equivalent of squaric acid to produce respective dyes each having an absorption maximum substantially coincident with the ruby-laser wavelength of 694 nm.

Abstract: A process for purifying indigo comprises extracting an aqueous leuco indigo alkali metal salt solution with an inert solvent under oxygen-excluding conditions and conventionally regenerating the indigo by oxidation.

Abstract: Disclosed herein are compounds and pharmaceutical compositions useful for combating picornaviruses and preventing or treating picornaviral infections. The compounds have the formula: ##STR1## wherein Het.sub.1 is chosen from the group consisting of oxazolyl, isoxazolyl, oxadiazolyl;Y is an alkylene bridge of 3 to 9 carbon atoms;Het.sub.2 is benzofuranyl or indolyl;R.sub.1 and R.sub.2 are each independently chosen from hydrogen, halo, acetyl, alkyl, alkenyl, amino, alkylthio, hydroxy, hydroxyalkyl, alkoxyalkyl, alkylthioalkyl, alkylsulfinyl alkyl, alkylsulfonylalkyl, alkoxy, nitro, carboxy, alkoxycarbonyl, dialkylaminoalkyl, alkylaminoalkyl, aminoalkyl, difluoromethyl, trifluromethyl, or cyano; andR.sub.3 is oxazolyl, oxadiazolyl, isoxazolyl or any of these substituted with alkyl, halo, alkoxyalkyl, cycloalkyl, haloalkyl, hydroxyalkyl, alkoxy, hydroxy, furyl, thienyl, or fluoroalkyl;the N-oxide thereof or a pharmaceutically acceptable acid addition salt thereof.

Abstract: The present invention provides novel aryl- and heteroarylethenylene derivatives which are useful as tyrosine kinase activity inhibitors.

Abstract: This invention relates to novel substituted tryptamine and phenalkylamine and related compounds, pharmaceutical compositions thereof and methods of using said compounds and compositions for a number of pharmaceutical indications including (but not limited to): 1. central nervous system and psychiatric disorders (e.g., sleep disorders, epilepsy and other convulsive disorders, anxiety, psychiatric diseases, neurodegenerative diseases, fever); 2. chronobiological-based disorders (e.g., jet lag, delayed sleep syndrome, shift-work, seasonal affective disorder); 3. endocrine indications (e.g., contraception and infertility, precocious puberty, premenstrual syndrome, hyperprolactinemia, growth hormone deficiency); 4. cancer and other proliferative diseases; 5. immune system disorders and conditions associated with senescence; 6. ophthalmological diseases; 7. animal breeding (e.g., regulation of fertility, puberty, pelage color).

Abstract: The present invention relates to chromogenic methylenepyrrolines and processes and intermediates for their preparation and to their use.The chromogenic methylenepyrroline compounds according to the invention have the formula (I) defined in claim 1.These colour formers are suitable in particular for thermographic recording processes and produce intensive red, violet, blue or brown colourations. They are distinguished by the fact that they do not require any conventional electron-withdrawing acid colour developer.

Abstract: A process for preparing halogenated indigo by reacting indigo with bromine and/or chlorine in the presence or absence of iodine as catalyst comprises using thionyl chloride as reaction medium.

Abstract: A process for the purification of indigo comprises treating the indigo with sulfuric acid to give indigo sulfate, separating off and subsequently hydrolyzing the latter to re-form indigo, and then treating the dye with dilute hydrogen peroxide solution.

Abstract: A process for purifying indigo comprises stripping the as-synthesized aqueous alkaline indoxylate solution before its oxidation to indigo of impurities in the absence of oxygen by distillation or by passing in steam or an inert gas and then treating the indigo precipitated on oxidation of the stripped indoxylate solution with dilute hydrogen peroxide solution.

Abstract: N-substituted maleimide represented by formula (2): ##STR1## is produced from N-substituted maleamic acid monoester represented by formula (1): ##STR2## in the presence of an acid catalyst by elmination of an alcohol from the monoester. The above N-substituted maleamic acid monoester represented by formula (1) is produced by esterification of N-substituted maleamic acid represented by formula (3): ##STR3## with an alcohol R.sup.2 -OH in the represence of an acid catalyst.

Abstract: A and A' are each hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy or aryloxy;X is cyano, nitro, COOR, SR, SOR or SOOR;R is H, C.sub.1-6 alkyl or aryl;n n' and n" are each 0 to 4; andm, m' and m" are each 1 to 4, have calcium channel blocking activity.

Abstract: Dyes of the formula ##STR1## where F is an (m+n)-valent radical of a quinophthalone, dioxazine, indigo, quinacridone, triphenylmethane or rhodamine dye, M.sup..sym. is H.sup..sym. or one equivalent of a metal cation, m is 0, 1 or 2 and n is 1, 2, 3 or 4, and their salts, are very useful for dyeing and printing paper. If they are used for wet-end dyeing, the waste water is virtually colorless. The colorations obtained exhibit good lightfastness and good bleeding fastness.